Does stevia lower blood pressure and blood sugar?

The sweetness in stevia leaves comes from a family of compounds called steviol glycosides. Of these, stevioside and rebaudioside A are the most abundant — and they behave differently. Stevioside is the form studied in most clinical trials on blood pressure and blood sugar. Rebaudioside A (reb A) is more common in commercial food products because it has a cleaner taste with less bitterness. Neither is digested or absorbed in the small intestine: they pass largely intact to the colon, where gut bacteria cleave off the sugar units to release steviol, which is then excreted. This metabolic pathway explains why stevia has negligible glycemic impact.⁶

Blood Pressure Effects

The most robust clinical evidence for stevia involves blood pressure. Stevioside appears to relax vascular smooth muscle, inhibit calcium channels in arterial walls, and modulate the renin-angiotensin system — three distinct mechanisms that collectively reduce peripheral resistance.⁵ Two multi-year randomized double-blind trials, both conducted in Chinese adults with mild essential hypertension, found that 500 mg of stevioside taken three times daily (1,500 mg/day) significantly reduced both systolic and diastolic blood pressure compared to placebo, with effects sustained across the full trial duration and good tolerability.^1,2

An important distinction: the 2015 meta-analysis by Onakpoya and Heneghan confirmed that these blood pressure effects are specific to stevioside. Rebaudioside A — the form used in most beverages and packaged foods — did not produce significant blood pressure reductions in clinical trials.⁴ If cardiovascular support is the goal, the form matters.

Blood Sugar Regulation

Stevioside has demonstrated genuine antihyperglycemic activity in type 2 diabetics. In a crossover study, supplementing a test meal with 1 g of stevioside reduced the incremental area under the postprandial glucose curve by 18% compared to a starch control.³ The proposed mechanisms include direct stimulation of insulin secretion from pancreatic beta cells and improvement of peripheral insulin sensitivity. Reducing post-meal glucose spikes is meaningful: repeated glycemic surges drive glycation, oxidative stress, and accelerate cardiovascular and renal complications in diabetes.

Anti-Inflammatory and Antioxidant Properties

Beyond the glycosides, stevia leaves contain flavonoids and phenolic acids with antioxidant and anti-inflammatory activity. Stevioside downregulates NF-κB — the master regulator of the inflammatory response — and reduces expression of COX-2 and iNOS, the enzymes responsible for inflammatory prostaglandins and nitric oxide.⁵ Stevia extracts also show free-radical scavenging activity in vitro and may protect against oxidative DNA damage. These findings come largely from cell and animal studies; direct human evidence for anti-inflammatory effects remains limited.

Practical Notes

• Stevioside (found in whole-leaf stevia and many supplement forms) is the form with clinical blood pressure and blood sugar evidence — not the same as highly purified reb A used in most commercial stevia products
• Heat-stable: suitable for cooking, baking, and hot beverages
• FDA classifies highly purified steviol glycosides as Generally Recognized as Safe (GRAS); both JECFA and EFSA have set an acceptable daily intake of 4 mg/kg body weight
• Bitter aftertaste varies significantly by product and individual taste perception — blending with erythritol or other fiber bulking agents can improve palatability in baking
• No established drug interactions at normal food-use levels, though blood-pressure lowering effects could theoretically add to antihypertensive medications

See our monk fruit page for comparison with another natural zero-calorie sweetener, and our artificial sweeteners page for context on why sweetener choice matters for long-term health.

Blood Pressure — 1-Year Randomized Controlled Trial

Chan et al. (2000) conducted a multicenter, double-blind, placebo-controlled trial in 106 Chinese adults aged 28–75 with mild-to-moderate hypertension (diastolic blood pressure 95–110 mmHg).¹ Participants received 500 mg stevioside three times daily or placebo. At 3 months, systolic and diastolic blood pressure decreased significantly in the stevioside group compared to both baseline and placebo, and these reductions persisted across the full year of follow-up. No clinically significant adverse effects were documented. The study was one of the first rigorous human trials to establish stevioside as a pharmacologically active antihypertensive agent.

Blood Pressure — 2-Year Randomized Controlled Trial

Hsieh et al. (2003) extended this investigation in a 2-year multicenter RCT of 174 Chinese adults aged 20–75 with mild essential hypertension (SBP 140–159, DBP 90–99 mmHg).² The stevioside arm (500 mg three times daily) demonstrated sustained and significant reductions in both systolic and diastolic blood pressure relative to placebo across the full 24-month period. Quality-of-life scores improved in the treatment arm. Biochemical monitoring revealed no significant changes in liver or kidney function markers, reinforcing the safety profile over long-term use. Together with the Chan 2000 trial, this provides the strongest clinical foundation for stevia's cardiovascular effects.

Postprandial Glucose in Type 2 Diabetes

Gregersen et al. (2004) performed an acute crossover study in 12 adults with type 2 diabetes.³ A standardized test meal supplemented with 1 g stevioside was compared against the same meal supplemented with 1 g corn starch. Stevioside produced an 18% reduction in the incremental area under the postprandial glucose curve (p < 0.05) and also reduced the insulin area under the curve, suggesting improvement in insulin action rather than solely an insulinotropic effect. The sample size is small and the design is single-meal and acute — it establishes mechanistic proof-of-concept rather than long-term glycemic control outcomes. Larger and longer trials are needed to confirm clinical significance for diabetes management.

Meta-Analysis — Cardiovascular Risk Factors

Onakpoya and Heneghan (2015) conducted a systematic review and meta-analysis of randomized clinical trials examining steviol glycosides' effects on blood pressure, fasting blood glucose, lipid profiles, and body weight.⁴ The pooled analysis found stevioside was associated with significant reductions in diastolic blood pressure and fasting blood glucose. Crucially, rebaudioside A showed no significant effect on any cardiovascular risk factor across the included trials — a form-specific distinction that is rarely highlighted in popular discussions of stevia research. The authors flagged substantial heterogeneity between studies and called for larger, standardized trials with longer follow-up periods.

Comprehensive Review of Biological Activities

Peteliuk et al. (2021) synthesized the available preclinical and clinical evidence on stevia's biological activities across multiple organ systems.⁵ Key findings included: anti-inflammatory activity via NF-κB suppression and COX-2/iNOS inhibition; antioxidant protection from both glycosides and leaf polyphenols; potential protective effects on kidney and liver function in animal models of toxin-induced damage; and preliminary antimicrobial activity against several pathogens including Streptococcus mutans, relevant to dental caries prevention. The review's safety assessment concluded that steviol glycosides show no mutagenicity, teratogenicity, or carcinogenicity at reviewed doses.

Updated Pharmacological and Safety Overview

Orellana-Paucar (2023) provided the most current comprehensive review of the pharmacological profile of steviol glycosides, noting growing evidence for anti-obesity, antifungal, and gut microbiome modulating effects.⁶ The gut microbiome data is emerging and mixed — some studies show beneficial prebiotic-like effects on short-chain fatty acid-producing bacteria, while others suggest selective inhibition of certain strains. The direction of net effects in humans under normal dietary doses is not yet established. Regulatory safety frameworks set by JECFA (ADI 0–4 mg/kg/day) and EFSA remain in place and continue to be supported by the accumulated safety literature.

Strength of Evidence

The blood pressure effects of stevioside are supported by two well-conducted multi-year multicenter RCTs and confirmed by meta-analysis — the strongest clinical foundation in the stevia evidence base. The antihyperglycemic effect in type 2 diabetics is mechanistically credible and demonstrated in a crossover trial, though larger and longer studies are needed to guide clinical recommendations. Anti-inflammatory and antioxidant properties are supported by strong preclinical mechanistic data but lack human trial confirmation. The safety record is excellent across decades of regulatory review and traditional use. The most important evidence gap remains long-term metabolic trials comparing stevioside with rebaudioside A, the form that dominates the commercial market, in well-characterized populations.